미국 - 영어 - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin macrocrystals capsules is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli, enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs, nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic

미국 - 영어 - NLM (National Library of Medicine)

major pharmaceuticals - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin macrocrystals capsules is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli, enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs, nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic

미국 - 영어 - NLM (National Library of Medicine)

bryant ranch prepack - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin macrocrystals capsules is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli, enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs, nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic

미국 - 영어 - NLM (National Library of Medicine)

northwind pharmaceuticals, llc - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin macrocrystals capsules is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli, enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin macrocrystals capsules and other antibacterial drugs, nitrofurantoin macrocrystals capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader t

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

ebos group ltd - lanolin 0.6% ((anhydrous) as viscolan); light liquid paraffin 8.75%{relative}; liquid paraffin 7.15%{relative}; lanolin oil 0.58%{relative}; liquid paraffin 15.86%{relative} - lotion - active: lanolin 0.6% ((anhydrous) as viscolan) light liquid paraffin 8.75%{relative} liquid paraffin 7.15%{relative} excipient: carbomer 934 docusate sodium glyceryl monostearate lauromacrogol 400 macrogol 200 macrogol stearate 2000 methyl hydroxybenzoate perfume givaudan pa-1614 (w6300-3) propyl hydroxybenzoate propylene glycol purified water trolamine active: lanolin oil 0.58%{relative} liquid paraffin 15.86%{relative} excipient: carbomer 934 docusate sodium glyceryl monostearate lauromacrogol 400 macrogol stearate 2000 methyl hydroxybenzoate n-(3-chloroallyl)hexaminium chloride perfume w6300-3 polyethylene glycol 400 dilaurate propyl hydroxybenzoate propylene glycol purified water trolamine

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

ebos group ltd - lanolin 3%{relative} (anhydrous); liquid paraffin 91.7%{relative}; lanolin oil 3%{relative}; liquid paraffin 91.7%{relative} - oil - active: lanolin 3%{relative} (anhydrous) liquid paraffin 91.7%{relative} excipient: oxybenzone givaudan gd-f 5604 polyethylene glycol 400 dilaurate solvent green 3 active: lanolin oil 3%{relative} liquid paraffin 91.7%{relative} excipient: oxybenzone gd 5604-16 polyethylene glycol 400 dilaurate solvent green 3

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docusate sodium 120mg - tablet - 120 mg - active: docusate sodium 120mg excipient: colloidal silicon dioxide heavy magnesium carbonate magnesium carbonate magnesium stearate microcrystalline cellulose opadry pink 85g64898 purified water sodium benzoate starch wheat starch - stool softener

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docusate sodium 50mg - tablet - 50 mg - active: docusate sodium 50mg excipient: colloidal silicon dioxide heavy magnesium carbonate magnesium carbonate magnesium stearate microcrystalline cellulose opadry orange 85g63181 sodium benzoate starch wheat starch - stool softener

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docusate sodium 50mg (50mg anhydrous = 50.69mg docusate sodium); sennosides 8mg equivalent to 11.27 mg standard raw material of 71% potency.;   - film coated tablet - active: docusate sodium 50mg (50mg anhydrous = 50.69mg docusate sodium) sennosides 8mg equivalent to 11.27 mg standard raw material of 71% potency.   excipient: calcium hydrogen phosphate dihydrate calcium phosphate carnauba wax colloidal silicon dioxide magnesium stearate maize starch maltodextrin microcrystalline cellulose opadry brown oy-26502 - the treatment of constipation.

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - docusate sodium 50.69mg equivalent to 50 mg docusate anhydrous; sennosides 8mg (available as 11.27mg of a 71% potent standard raw material);   - film coated tablet - active: docusate sodium 50.69mg equivalent to 50 mg docusate anhydrous sennosides 8mg (available as 11.27mg of a 71% potent standard raw material)   excipient: calcium hydrogen phosphate dihydrate calcium phosphate carnauba wax colloidal silicon dioxide magnesium stearate maize starch maltodextrin microcrystalline cellulose opadry brown oy-26502 - the treatment of constipation.